What is the Morphine Milligram Equivalent (MME) of intravenous (IV) hydromorphone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Morphine Milligram Equivalent (MME) of IV Hydromorphone

The MME conversion factor for IV hydromorphone is 4, meaning 1 mg of IV hydromorphone equals 4 mg of oral morphine equivalents. 1

Standard Conversion Factor

  • The CDC Guideline for Prescribing Opioids for Chronic Pain establishes that hydromorphone has a conversion factor of 4 when calculating morphine milligram equivalents (MME). 1
  • This means that 1 mg of hydromorphone = 4 mg MME, regardless of route of administration for MME calculation purposes. 1

Clinical Context and Potency Considerations

While the MME conversion factor is standardized at 4:1 for calculation purposes, it's important to understand that actual clinical potency varies by route:

  • For equianalgesic dosing conversions (not MME calculations), IV morphine to IV hydromorphone uses approximately a 5:1 ratio, where 10 mg IV morphine equals 2 mg IV hydromorphone. 2, 3
  • Research data suggests IV hydromorphone may be 8.5 times as potent as IV morphine on a milligram basis in actual clinical practice. 4
  • The higher clinical potency (5-7 times more potent than morphine) allows for smaller volume administration, which is beneficial in acute care settings. 2

Important Distinction

  • The MME conversion factor of 4 is specifically for calculating total morphine milligram equivalents for comparison and monitoring purposes, such as tracking opioid burden or regulatory compliance. 1
  • This differs from equianalgesic dosing ratios used when actually switching patients between medications, where incomplete cross-tolerance must be considered and doses should be reduced by 25-50%. 3, 1
  • When converting between opioids in clinical practice, the 5:1 ratio (IV morphine to IV hydromorphone) with dose reduction for incomplete cross-tolerance is recommended, not the MME factor. 2, 3

References

Guideline

Opioid Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hydromorphone Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Hydromorphone Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hydromorphone: pharmacology and clinical applications in cancer patients.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001

Related Questions

What is the morphine (opioid analgesic) equivalent dose of 25 milligrams (mg) of hydromorphone (potent opioid analgesic)?
What are the morphine (opioid analgesic) equivalents of hydromorphone (HM) intravenous (IV) and subcutaneous (SQ)?
Can 1 milligram (mg) tablets of hydromorphone be split?
What is the equivalent dose of hydromorphone (Hydromorph Contin) BID for a patient taking morphine (Contin) 100mg BID?
What is the Morphine Equivalent Dose (MEDD) of 18mg hydromorphone Intravenous (IV)?
Is there an indication for using nitazoxanide (antiparasitic medication) as a prophylactic measure every year or every 6 months in individuals at high risk of parasitic infections?
What are the treatment options for erectile dysfunction in a 76-year-old male with a history of benign prostatic hyperplasia (BPH), status post Transurethral Resection of the Prostate (TURP) 18 months ago, taking Perindopril (Angiotensin-Converting Enzyme Inhibitor) 8 mg, Indapamide (Thiazide-like Diuretic) 2.5 mg, and Amlodipine (Calcium Channel Blocker) 5 mg for well-controlled hypertension with a blood pressure of approximately 110/70 mmHg?
How is sliding scale insulin administered to patients with diabetes, particularly those with type 2 diabetes or unstable glucose levels?
What is the treatment for liver toxicity associated with Ipilimumab (Yervoy) and Nivolumab (Opdivo) therapy?
What is the best approach to manage a patient, likely an adult with a possible history of cancer, presenting with a desmoid tumor and paraneoplastic myopathy?
What is the best course of action for a patient with leukopenia (low White Blood Cell count), lymphocytosis (high lymphocytes), and neutropenia (low absolute neutrophils)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.